Private Securities Litigation Reform Act

BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates

Retrieved on: 
Tuesday, November 15, 2022

TEL AVIV, Israel, Nov. 15, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported third quarter financial results and recent corporate and portfolio updates.

Key Points: 
  • "Additionally, working with our collaborators, we advanced motixafortide development programs for pancreatic cancer, reflecting motixafortide's potential broad clinical utility.
  • Finally, we anticipate sharing data from the Phase 1/2a trial of our solid tumor investigational immunotherapy AGI-134 prior to year-end.
  • A dial-in replay of the call will be available untilNovember 17, 2022; please dial +1-888-295-2634 from the US or +972-3-925-5903 internationally.
  • BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

JinkoSolar's 182 mm TOPCon Module Reaches Highest Conversion Efficiency of 23.86%

Retrieved on: 
Tuesday, November 15, 2022

The module adopted JinkoSolar's latest TOPCon cell technology and advanced welding and packaging technology and achieved conversion efficiency of 23.86% for the first time for 2 mm2 above large-size solar modules.

Key Points: 
  • The module adopted JinkoSolar's latest TOPCon cell technology and advanced welding and packaging technology and achieved conversion efficiency of 23.86% for the first time for 2 mm2 above large-size solar modules.
  • The advanced welding and packaging technology effectively reduces the internal resistance loss of the module, while significantly improving conversion efficiency.
  • Dr. Hao Jin, Chief Technology Officer of JinkoSolar Co., Ltd., commented, "We are pleased to make another breakthrough in module conversion efficiency, leveraging our accumulated experience and continuous efforts in N-type technology R&D and mass production.
  • JinkoSolar (NYSE: JKS) is one of the largest and most innovative solar module manufacturers in the world.

Lightning eMotors Announces Collaboration with HEVO Inc. to Wirelessly Charge Electric Vehicle Fleets

Retrieved on: 
Tuesday, November 15, 2022

The demo vehicle will then be showcased to Lightning and HEVO fleet customers throughout North America.

Key Points: 
  • The demo vehicle will then be showcased to Lightning and HEVO fleet customers throughout North America.
  • The HEVO roadmap includes expanded energy delivery options of 11kW, 25kW, 50kW, and 100-300kW to service fleets with a variety of dwell times and power needs.
  • HEVO's Founder & CEO, Jeremy McCool, commented: "We are impressed with Lightning eMotors' high-quality products and focus on innovation.
  • Lightning eMotors' Co-Founder & CEO, Tim Reeser, added: "We are excited to be first-to-market with medium-duty production vehicles equipped with wireless charging.

Bright Scholar Schedules Unaudited Financial Results for the Fourth Fiscal Quarter And Fiscal Year 2022 Ended August 31, 2022

Retrieved on: 
Tuesday, November 15, 2022

FOSHAN, China, Nov. 15, 2022 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar," the "Company," "we" or "our") (NYSE: BEDU), a global premier education service company, today announced that it will release its unaudited financial results for the fourth fiscal quarter and fiscal year ended August 31, 2022, on November 29, 2022, after the US market closes.

Key Points: 
  • FOSHAN, China, Nov. 15, 2022 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar," the "Company," "we" or "our") (NYSE: BEDU), a global premier education service company, today announced that it will release its unaudited financial results for the fourth fiscal quarter and fiscal year ended August 31, 2022, on November 29, 2022, after the US market closes.
  • Bright Scholar is a global premier education service company, which primarily provides quality international education to global students and equip them with the critical academic foundation and skillsets necessary to succeed in the pursuit of higher education.
  • Bright Scholar also complements its international offerings with Chinese government-mandated curriculum for students who wish to maintain the option of pursuing higher education in China.
  • Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission.

Quhuo Reported the Unaudited Financial Results for the First Half of 2022, Achieving an 89.6% Year-over-Year Increase in the Gross Profit

Retrieved on: 
Tuesday, November 15, 2022

In the first half of 2022, Quhuo maintained its strategy in 2021 of increasing revenues before enhancing profitability.

Key Points: 
  • In the first half of 2022, Quhuo maintained its strategy in 2021 of increasing revenues before enhancing profitability.
  • The overall financial performance of the first half of 2022 demonstrated the effectiveness of Quhuo's strategic planning and implementation.
  • The Company's mobility service solutions and housekeeping and accommodation solutions have also achieved excellent preperformance, achieving year-over-year increase of 32.2% and 24.7%, respectively.
  • Quhuo Limited (NASDAQ: QH) ("Quhuo" or the "Company") is a leading gig economy platform focusing on local community-centered services inChina.

Charlotte's Web Announces US$56.8 Million Investment from BAT

Retrieved on: 
Tuesday, November 15, 2022

The Investment provides substantial liquidity at an attractive cost of capital for Charlotte's Web.

Key Points: 
  • The Investment provides substantial liquidity at an attractive cost of capital for Charlotte's Web.
  • Upon closing of this investment, Charlotte's Web will have pro-forma cash and short-term investments of approximately US$65 million.
  • The Investment was made by BAT's subscription for an unsecured convertible debenture issued by Charlotte's Web (the "Debenture") in the principal amount of C$75.3 million due November 14, 2029.
  • Concurrently with entering into the Debenture, BAT and Charlotte's Web entered into an investor rights agreement (the "IRA").

Allot Board Nominates Cynthia L. Paul to Serve as a Director

Retrieved on: 
Tuesday, November 15, 2022

Ms. Paul served as Chairperson of the Board of Directors of Conexant Systems, LLC, a semiconductor company, from 2013 until 2017.

Key Points: 
  • Ms. Paul served as Chairperson of the Board of Directors of Conexant Systems, LLC, a semiconductor company, from 2013 until 2017.
  • Ms. Paul joined SFM in 2000 and served as a SFM representative for the Council on Foreign Relations and on SFM's Investment Committee.
  • Ms. Paul is an advisory board member and former board member of AlphaSense Inc., a SaaS company providing intelligent search to enterprise customers.
  • "We are extremely pleased that Ms. Paul has accepted our nomination to be appointed to the Company's Board of Directors," said Yigal Jacoby, Allot's Chairman of the Board.

Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA

Retrieved on: 
Tuesday, November 15, 2022

STOCKHOLM, Nov. 15, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT)(Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Products Administration ("NMPA") has accepted Everest Medicines' (HKEX 1952.HK, "Everest") New Drug Application ("NDA") for Nefecon.

Key Points: 
  • STOCKHOLM, Nov. 15, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT)(Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Products Administration ("NMPA") has accepted Everest Medicines' (HKEX 1952.HK, "Everest") New Drug Application ("NDA") for Nefecon.
  • In December 2020, the NMPA recommended Breakthrough Therapy Designation ("BTD") for Nefecon for the treatment of IgAN.
  • Chronic kidney disease is one of the most serious public health problems in China, where IgAN is estimated by Everest to affect around five million people.
  • In June 2019, Calliditas entered into a license agreement with Everest to develop and commercialize Nefecon in Greater China and Singapore in IgAN.

Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA

Retrieved on: 
Tuesday, November 15, 2022

STOCKHOLM, Nov. 15, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT)(Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Products Administration ("NMPA") has accepted Everest Medicines' (HKEX 1952.HK, "Everest") New Drug Application ("NDA") for Nefecon.

Key Points: 
  • STOCKHOLM, Nov. 15, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT)(Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Products Administration ("NMPA") has accepted Everest Medicines' (HKEX 1952.HK, "Everest") New Drug Application ("NDA") for Nefecon.
  • In December 2020, the NMPA recommended Breakthrough Therapy Designation ("BTD") for Nefecon for the treatment of IgAN.
  • Chronic kidney disease is one of the most serious public health problems in China, where IgAN is estimated by Everest to affect around five million people.
  • In June 2019, Calliditas entered into a license agreement with Everest to develop and commercialize Nefecon in Greater China and Singapore in IgAN.

Kelyniam Global Announces 3rd Quarter Results

Retrieved on: 
Tuesday, November 15, 2022

CANTON, Conn., Nov. 15, 2022 /PRNewswire/ -- Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its quarter ended September 30, 2022. 

Key Points: 
  • CANTON, Conn., Nov. 15, 2022 /PRNewswire/ -- Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its quarter ended September 30, 2022.
  • "The quarter over quarter results were particularly exciting because we had an elevated 3rd quarter in 2021 due to pent up Covid related demand.
  • Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers.
  • Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes.